Literature DB >> 22205577

Expression levels of microRNA-192 and -215 in gastric carcinoma.

Yeunpo Chiang1, Xin Zhou, Zhenning Wang, Yongxi Song, Zhuangkai Liu, Fang Zhao, Jinliang Zhu, Huimian Xu.   

Abstract

MicroRNAs (miRNAs) are small, non-coding RNAs of endogenous origin. Accumulating studies have shown aberrant miRNA expression plays an important role in many tumor types. miR-192 and -215, which have the same "seed region", have not been comprehensively investigated using a large number of cases in gastric cancer. The total RNA was extracted from 118 gastric cancer tissues and three gastric cancer cell lines as well as matched non-tumor adjacent tissues (NATs). After polyadenylation and reverse transcription, expression levels of miR-192 and -215 were determined by real-time PCR and calculation using the 2(-∆∆CT) method for evaluation of the association between miR-192, and -215 expression levels and clinicopathological characteristics. There were no significant differences in miR-192 and -215 expression levels between gastric cancer tissues and non-tumor counterparts (both p > 0.05, paired t-test). Interestingly, miR-192 and -215 were down-regulated in MGC-803 cells, BGC-823 cells and SGC-7901 cells (all p < 0.01, paired t-test). Also, the down-regulation of miR-192 and -215 was demonstrated to be associated with increased tumor sizes (both p = 0.003, Mann-Whitney U test) and advanced Borrmann type tumors (p = 0.015 and p = 0.044, respectively, Kruskal-Wallis H test). Moreover, the expression of miR-192 was significantly lower in the pT4 stage of gastric cancer than in pT1, pT2 and pT3 stages (p = 0.026). Furthermore, there was a strong correlation between miR-192 and -215 in gastric cancer tissues (p < 0.001, Pearson regressions). miR-192 and -215 might be related to the proliferation and invasion of gastric cancer. Potentially, they could become important biomarkers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22205577     DOI: 10.1007/s12253-011-9480-x

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  35 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections.

Authors:  Sergio Marchini; Duccio Cavalieri; Robert Fruscio; Enrica Calura; Daniela Garavaglia; Ilaria Fuso Nerini; Costantino Mangioni; Giorgio Cattoretti; Luca Clivio; Luca Beltrame; Dionyssios Katsaros; Luca Scarampi; Guido Menato; Patrizia Perego; Giovanna Chiorino; Alessandro Buda; Chiara Romualdi; Maurizio D'Incalci
Journal:  Lancet Oncol       Date:  2011-02-21       Impact factor: 41.316

3.  Altered expression of MiR-148a and MiR-152 in gastrointestinal cancers and its clinical significance.

Authors:  Yue Chen; Yongxi Song; Zhenning Wang; Zhenyu Yue; Huimian Xu; Chengzhong Xing; Zhuangkai Liu
Journal:  J Gastrointest Surg       Date:  2010-04-27       Impact factor: 3.452

4.  miR-132 and miR-212 are increased in pancreatic cancer and target the retinoblastoma tumor suppressor.

Authors:  Jong-Kook Park; Jon C Henry; Jinmai Jiang; Christine Esau; Yuriy Gusev; Megan R Lerner; Russell G Postier; Daniel J Brackett; Thomas D Schmittgen
Journal:  Biochem Biophys Res Commun       Date:  2011-02-15       Impact factor: 3.575

5.  Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues.

Authors:  Junming Guo; Ying Miao; Bingxiu Xiao; Rong Huan; Zhen Jiang; Dan Meng; Yanjun Wang
Journal:  J Gastroenterol Hepatol       Date:  2008-11-03       Impact factor: 4.029

6.  Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215.

Authors:  Sara A Georges; Matthew C Biery; Soo-Yeon Kim; Janell M Schelter; Jane Guo; Aaron N Chang; Aimee L Jackson; Michael O Carleton; Peter S Linsley; Michele A Cleary; B Nelson Chau
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

7.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis.

Authors:  Nozomu Yanaihara; Natasha Caplen; Elise Bowman; Masahiro Seike; Kensuke Kumamoto; Ming Yi; Robert M Stephens; Aikou Okamoto; Jun Yokota; Tadao Tanaka; George Adrian Calin; Chang-Gong Liu; Carlo M Croce; Curtis C Harris
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

8.  Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers.

Authors:  George Adrian Calin; Cinzia Sevignani; Calin Dan Dumitru; Terry Hyslop; Evan Noch; Sai Yendamuri; Masayoshi Shimizu; Sashi Rattan; Florencia Bullrich; Massimo Negrini; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-18       Impact factor: 11.205

9.  Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development.

Authors:  Flavia Pichiorri; Sung-Suk Suh; Alberto Rocci; Luciana De Luca; Cristian Taccioli; Ramasamy Santhanam; Wenchao Zhou; Don M Benson; Craig Hofmainster; Hansjuerg Alder; Michela Garofalo; Gianpiero Di Leva; Stefano Volinia; Huey-Jen Lin; Danilo Perrotti; Michael Kuehl; Rami I Aqeilan; Antonio Palumbo; Carlo M Croce
Journal:  Cancer Cell       Date:  2010-10-19       Impact factor: 31.743

10.  miR-34a and miR-15a/16 are co-regulated in non-small cell lung cancer and control cell cycle progression in a synergistic and Rb-dependent manner.

Authors:  Nora Bandi; Erik Vassella
Journal:  Mol Cancer       Date:  2011-05-16       Impact factor: 27.401

View more
  15 in total

1.  miR-211 promotes non-small cell lung cancer proliferation by targeting SRCIN1.

Authors:  Leiguang Ye; Hui Wang; Baogang Liu
Journal:  Tumour Biol       Date:  2015-08-16

Review 2.  Therapeutic potential of microRNAs for the treatment of renal fibrosis and CKD.

Authors:  Wenshan Lv; Fan Fan; Yangang Wang; Ezekiel Gonzalez-Fernandez; Chen Wang; Lili Yang; George W Booz; Richard J Roman
Journal:  Physiol Genomics       Date:  2017-11-10       Impact factor: 3.107

3.  MicroRNA-495 suppresses human renal cell carcinoma malignancy by targeting SATB1.

Authors:  Cai Lv; Zhiming Bai; Zhenxiang Liu; Pengcheng Luo; Jie Zhang
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

Review 4.  MicroRNA dysregulation in rhabdomyosarcoma: a new player enters the game.

Authors:  Zheng Li; Xin Yu; Jianxiong Shen; Yang Liu; Matthew T V Chan; William K K Wu
Journal:  Cell Prolif       Date:  2015-07-23       Impact factor: 6.831

Review 5.  MicroRNA expression and its implications for diagnosis and therapy of gallbladder cancer.

Authors:  Zheng Li; Xin Yu; Jianxiong Shen; Priscilla T Y Law; Matthew T V Chan; William K K Wu
Journal:  Oncotarget       Date:  2015-06-10

6.  A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease.

Authors:  Youwen Tan; Guohong Ge; Tengli Pan; Danfeng Wen; Jianhe Gan
Journal:  PLoS One       Date:  2014-08-20       Impact factor: 3.240

Review 7.  Potential Diagnostic, Prognostic and Therapeutic Targets of MicroRNAs in Human Gastric Cancer.

Authors:  Ming-Ming Tsai; Chia-Siu Wang; Chung-Ying Tsai; Hsiang-Wei Huang; Hsiang-Cheng Chi; Yang-Hsiang Lin; Pei-Hsuan Lu; Kwang-Huei Lin
Journal:  Int J Mol Sci       Date:  2016-06-16       Impact factor: 5.923

8.  MUC1 regulates expression of multiple microRNAs involved in pancreatic tumor progression, including the miR-200c/141 cluster.

Authors:  Ashley M Mohr; Jennifer M Bailey; Michelle E Lewallen; Xiang Liu; Prakash Radhakrishnan; Fang Yu; William Tapprich; Michael A Hollingsworth
Journal:  PLoS One       Date:  2013-10-15       Impact factor: 3.240

9.  Studying the system-level involvement of microRNAs in Parkinson's disease.

Authors:  Paulami Chatterjee; Malay Bhattacharyya; Sanghamitra Bandyopadhyay; Debjani Roy
Journal:  PLoS One       Date:  2014-04-01       Impact factor: 3.240

10.  Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of Imatinib.

Authors:  Kazuma Ohyashiki; Tomohiro Umezu; Seiichiro Katagiri; Chiaki Kobayashi; Kenko Azuma; Tetsuzo Tauchi; Seiichi Okabe; Yutaka Fukuoka; Junko H Ohyashiki
Journal:  Int J Mol Sci       Date:  2016-04-15       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.